| 生物活性 | |||
|---|---|---|---|
| 描述 | Mizagliflozin (DSP-3235 free base) is a potent, orally active inhibitor specifically targeting the SGLT1 transporter, with a Ki of 27 nM for human SGLT1, showcasing a 303-fold selectivity over SGLT2. This selectivity positions Mizagliflozin as a promising antidiabetic agent capable of modifying postprandial blood glucose levels. Additionally, it has shown potential in alleviating symptoms of chronic constipation[1]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.77mL 0.35mL 0.18mL |
8.85mL 1.77mL 0.89mL |
17.71mL 3.54mL 1.77mL |
| 参考文献 |
|---|